EhmetDx revealed on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance for its 3D CBCT positioning software for patient treatment.

In December 2018, the 3D CBCT positioning system will be used to precisely guide the position of the proton beam in patient treatment at the McLaren Proton Therapy Centre.

With patient treatment imminent, the company's team will turn its efforts to focus on commercialisation of the Mammoknife: the world's first self-shielded, linac-based breast cancer radiotherapy device that will raise the standard of treatment for women globally, added its founder and CEO Michael Teicher.

Headquartered in Plymouth, Michigan, EhmetDx is commercialising the latest identifiable needs of the medical market. It is a consortium of health care focused engineers, scientists and executives from diverse backgrounds that have collaborated to bring a sense of integrity and execution to the device industry.